Knowledge Distillery

Alzheimer’s disease (AD) and COVID-19 share common risk factors including hypertension. Angiotensin converting enzyme inhibitors (ACEI) and…

Data from the early pandemic revealed that 0.62% of children hospitalised with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had an…

The authors compared mortality rates in 2020 (March-December) with rates in 2019 for the same period among 53 640 888 Medicare enrollees >…

To determine the impact of MS disease-modifying therapies (DMTs) on the development of cellular and humoral immunity to SARS-CoV-2 infection.

There is strong evidence for brain-related abnormalities in COVID-19. It remains unknown however whether the impact of SARS-CoV-2 infection can be…

Despite the increasing number of reports on the spectrum of neurological manifestations of COVID-19 (neuro-COVID), few studies have assessed short-…

Recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection appears exponential, leaving a tail of patients reporting various…

In this article the authors conducted a systematic review and meta-analysis of the cognitive effects of coronavirus disease 2019 (COVID-19) in adults…

As a global health emergency, the rapid spread of the novel coronavirus disease (COVID‐19) led to the implementation of widespread restrictions (e.g.,…

Fatigue and cognitive difficulties are reported as the most frequently persistent symptoms in patients after mild SARS-CoV-2 infection.

Findings of association between COVID-19 and stroke remain inconsistent, ranging from significant association, absence of association to less than…

The global spread of COVID-19 has raised concerns about its possible impact on mental health. People living with multiple sclerosis (PwMS) are…